Dose-dependent pharmacokinetics of dexamethasone

Area of Science:

• Endocrinology
• Pharmacology

Background:

• Dexamethasone is a potent synthetic glucocorticoid.
• Understanding its pharmacokinetic profile and impact on the hypothalamic-pituitary-adrenal (HPA) axis is crucial for clinical application.

Purpose of the Study:

• To investigate the dose-dependent pharmacokinetics of dexamethasone.
• To evaluate the influence of dexamethasone on endogenous cortisol secretion in healthy females.

Main Methods:

• Healthy female participants received oral or intramuscular dexamethasone at doses ranging from 0.5 to 3.0 mg.
• Plasma levels of dexamethasone were measured over time.
• Endogenous cortisol secretion was assessed by measuring its suppressive effects at various time points post-administration.

Main Results:

• Maximum plasma levels of dexamethasone were achieved between 1.6-2.0 hours, irrespective of administration route or dose.
• Pharmacokinetic parameters (AUC, Vd, CL, Cmax) did not increase proportionally with dose for oral administration (0.5-1.5 mg), suggesting non-linear kinetics possibly due to bioavailability issues.
• Cortisol suppression was dose-dependent at 24 hours, with higher doses (1.5 mg p.o., 3.0 mg i.m.) showing more pronounced effects than lower doses (0.5 mg p.o.).
• Administration every second day also demonstrated significant cortisol suppression, with integral reduction ranging from 44-65% for 0.5 mg and 59-62% for 1.5 mg.

Conclusions:

• Dexamethasone exhibits dose-dependent effects on cortisol suppression, particularly at the 24-hour mark.
• Potential bioavailability differences between oral and intramuscular routes may influence dexamethasone pharmacokinetics.
• The findings highlight the importance of dose selection for dexamethasone therapy to manage HPA axis suppression effectively.